Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanzanian pediatric malaria treatment efficacy study of artemether-lumefantrine and artesunate-amodiaquine
ACTRN12622001243707Phase 4Completed
- Sponsor
- National Institute for Medical Research
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether, lumefantrine, artesunate and amodiaquine in malaria and Falciparum malaria (PF) (2 arms), sponsored by National Institute for Medical Research. Primary endpoint: PCR-corrected treatment failure rate. Started May 2022; status: completed.
02
Drugs
artemetherlumefantrineartesunateamodiaquine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12622001243707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001243707.